LEXX · Lexaria Bioscience Corp.
$13.45
+0.98 (+7.82%)
At close · Sep 2
Going-concern doubt
— flagged Jul 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The recurring losses and negative net cash flows raise substantial doubt as to the Company's ability to continue as a going concern. However, we have also concluded that our existing cash, combined with inflows expected from executed license agreements, will not be sufficient to meet the Company's financial obligations for the twelve-month period following the issuance of these consolidated financial statements. Accordingly, there is substantial doubt as to our ability to continue as a going concern within one year from the date of issuance of these financial statements.”View the 10-Q filed Jul 13, 2026
Market Cap
$20.61M
Shares
1.65M
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2025-12-19 | New | Biotechnology | $3,500,004 | $3,500,004 | 06b |
| 2025-10-01 | New | Biotechnology | $4,000,000 | $4,000,000 | 06b |
| 2024-10-16 | New | Pharmaceuticals | $5,000,000 | $5,000,000 | 06b |
| 2024-05-02 | New | Pharmaceuticals | $364,629 | $364,629 | 06b |
| 2024-02-16 | New | Pharmaceuticals | $3,600,003 | $3,600,003 | 06b |
| 2023-10-04 | New | Pharmaceuticals | $1,569,780 | $1,569,780 | 06b |
| 2021-12-20 | New | Biotechnology | $1,200,000 | $1,200,000 | 06b |
| 2021-07-27 | New | Biotechnology | $85,000 | $85,000 | 06b |
| 2020-07-08 | New | Biotechnology | $100,000 | $100,000 | 06b |
| 2020-05-13 | New | Other | $2,039,228 | $2,039,228 | 06b |
Showing 1–10 of 10 filings